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TRANSPLANT A nON has been built on the founda-tion of using drug thera.py to nonspecifically suppress 
the recipient immune response. Failure to achieve ade-
quate immunosuppression is associated with a high inci-
dence of graft loss from rejection. The present goal of 
immunosuppressive regimens is to suppress the immune 
response to the allograft while preserving sufficient immu-
nity to avoid opportunistic infections and malignancies. In 
addition, these must be achieved while minimizing the 
inherent adverse effects of a particular drug. The ultimate 
goal of immunomodulation is to achieve donor-specific 
tolerance without alterations in immunity to other anti-
gens. 
The purpose of this dissertation is to briefly summarize 
the mechanism and role of current and potential future 
immunosuppressive agents in solid organ transplantation. 
Since an exhaustive review of these agents is not possible, 
the reader is referred to a number of such reviews. 1-3 
CURRENT IMMUNOSUPPRESSIVE AGENTS 
Corticosteroids possess an antirejection property and have 
been utilized in almost all baseline immunosuppressive 
regimens. Current baseline doses of steroids range around 
.1 to .2 mg/kg per day. Steroids are also utilized as the first 
line of treatment of acute rejection episodes, at higher 
doses approximating 10 to 15 mglkg. The mechanisms of 
action are several-fold: (1) antiinflammatory, stabilizing 
lysosomal membranes, suppressing prostaglandin synthe-
sis; (2) suppressing IL-l synthesis by macrophages by 
inhibiting IL-l gene transcription; (3) inhibiting IL-6 gene 
transcription; and (4) Iympholysis. The side effects are 
numerous and are related to the total dose and duration of 
administration. These include mood swings, weight gain, 
hypertension, diabetes'mellitus, ulcerogenesis, osteoporo-
sis, acne, growth retardation in children, aseptic necrosis 
of the femoral head, glaucoma, and cataracts. 
Antilymphocyte antibody preparations are heterologous 
antilymphocyte preparations. Either the serum fraction 
[antilymphocyte serum (ALS)] or the immunoglobulin 
fraction [antilymphocyte globulin (ALG)) can be utilized. 
The only FDA commercially available ALG is ATGAM 
(Upjohn), although MALG (University of Minnesota) has 
been utilized by a number of centers. ALS and ALG 
preparations are utilized for the treatment of rejection, 
generally those considered as steroid resistant, although 
induction therapy with these preparations have allowed for 
lowered doses of cyclosporine (Cy A) in the early post-
transplant period. The mechanism of action is probably by 
depletion of lymphocytes via antibody-mediated destruc-
tion, although other mechanisms may also be important. 
The side effects are related t6 the limitations of crude 
antisera preparations. These include fever, chills, Gl dis-
tress, myalgias, arthralgias, anaphylactoid reactions, se-
rum sickness, thrombocytopenia, anemia, and leukopenia. 
Monoclonal anti-T-cell antibodies are the result of hy-
bridoma technology, allowing for easy quantification while 
minimizing lot-to-Iot variation. The antibody is of murine 
origin, with defined specificity to the cm receptor asso-
ciated with the T-cell receptor. To date, only 0 KTJ (Ortho 
Pharmaceuticals) has been approved, but a number of 
other preparations are being tested in clinical trials (see 
next section). Like ALG or ALS preparations, the princi-
ple use of OKTJ has been for reversal of steroid-resistant 
acute cellular rejections. OKT3 has also been utilized in a 
number of induction protocols, again to minimize early use 
of Cy A to prevent nephrotoxicity. The most important 
mechanism of OKT3 is its ability to modulate the antigen 
recognition unit of the T cell. thereby neutralizing lympho-
cyte function. While effective in the treatment of rejection, 
the development of human antibodies to mouse proteins 
limits the Length of treatment. The side effects following 
OKTJ are similar to that of ALG or ALS, although 
thrombocytopenia. anemia, and leukopenia are not gener-
ally seen with OKT3 administration. An enhanced suscep-
tibility to viral infections following OKT3 has been re-
ported. 
Azathioprine is an imidazole derivative of 6-mercap-
topurine, which is the active metabolite following hepatic 
metabolism. 6-Mercaptopurine is a purine analog which 
inhibits a number of important purine nucleotide synthetic 
enzymes. Azathioprine (Imuran, Up john) was one of the 
first widely used immunosuppressive agents for clinical 
transplantation. When utilized as the principle immuno-
suppressive agent, relatively high doses of 3 to 5 mglkg per 
day are required. When used as part of a combination 
regimen, maintenance doses of 1 to 2 mg/kg per day are 
used. The drug is readily absorbed after oral administra-
tion, and the intravenous (IV) dose is the same as that for 
oral dosing. The side effects of azathioprine are related to 
the DNA inhibitory properties. Myelosuppression is the 
limiting factor in its use and this effect is dose dependent. 
Cy A is a cyclic polypeptide derived from a soil fungus, 
Application of Cy A to clinical transplantation has been 
considered to be the reason for a quantum improvement in 
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patient and graft survival. when compared to azathioprine-
based immunosuppression. Cy A is a lipid-soluble com-
pound, which requires bile salts for absorption. The oral 
bioavailability of CyA is approximately 30%, and dose 
changes must be made for IV dosing. Monitoring of trough 
levels is common, utilizing any of a number of different 
assay systems. CyA inhibits the transcription of IL-2 
mRNA, thereby inhibiting T-cell proliferation. In addition, 
other cytokine gene expression is inhibited. Gamma-inter-
feron and IL-3 secretion by T cells are also inhibited by 
Cy A. This drug represents a newer generation of nonspe-
cific immunosuppression, since the humoral arm of the 
immune response is relatively spared from the effects of 
Cy A. There is no myelosuppressive side effects of the 
drug, although there are a number of other side effects 
associated with long-term CyA use. Nephrotoxicity, hy-
pertension, hyperkalemia. hirsuitism, gingival hypertro-
phy, and tremors are relatively common side effects of 
Cy A. Because of the relatively specific effect of Cy A on 
T-cell activity, a higher incidence of posttransplant lym-
phoproliferative diseases is seen. 
FUTURE IMMUNOSUPPRESSIVE AGENTS 
Investigational immunosuppressive agents include: FK 
506 (inhibits cytokine synthesis), rapamycin (inhibits cy-
to kine synthesis), brequinar (inhibits enzymes of the py-
rimidine nucleotide synthesis pathway), mycophenolic 
acid (inhibits enzymes of the purine salvage pathway). and 
a number of monoclonal antibodies with varying specific-
ities. Agents with significant experience in ongoing clinical 
trials will be presented. Again, readers are referred to 
more comprehensive reviews on these newer immunosup-
pressive agents.4-6 
Mycophenolic acid was used as an agent for the treat-
ment of refractory psoriasis. This drug was relatively well 
tolerated. the principle side effects being: leukopenia. 
mucositis. and GI upset. There was reportedly a higher 
incidence of upper respiratory infections and, in long-
term-treated patients, a higher incidence of skin cancers. 
RS61443, is an analogue of mycophenolic acid, with en-
hanced oral bioavailability. Like mycophenolic acid, 
RS61443 (Syntex Pharmaceuticals) inhibits inosine mono-
phosphate dehydrogenase and guanosine monophosphate 
synthetase, both key enzymes which regulate the purine 
nucleotide salvage pathway.7 This agent has been studied 
in clinical trials, as primary therapy along with CyA and 
steroids, in kidney transplantation, as well as in "rescue" 
therapy in patients with refractory organ rejection.6 Pre-
liminary results suggest that this drug is relatively well 
tolerated as doses up to 3.5 to 4.0 gld. 
FK 506 is a macrolide antibiotic, derived from the 
fermentation product of Streptomyces tsukubaensis. FK 
506 is a hydrophobic compound, so that pharmaceutical 
formulation requires a solubilizing agent. The oral bio-
availability varies considerably among individuals, and 
averages 25%. Oral absorption is not dependent upon bile 
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salt presence, which is an important factor in liver trans-
plant patients. Metabolism is almost entirely by the liver 
by the cytochrome P-450 IA and IlIA families. FK 506 
binds to specific intracellular receptors, termed FKBP (FK 
506 binding proteins). Like cyclophylin (the receptor for 
CyA) , these receptors possess peptidyl-prolyl cis-trans 
isomerases. FK 506 inhibits the ca1cium-dependent path-
way of T-cell activation, and inhibits transcription of 
various cytokine mRNAs. FK 506 has been utilized in a 
number of clinical situations, both as "rescue" and as 
primary therapy.9 It has been used in liver. kidney, hean. 
and lung transplantation. FK 506 appears to be a potent 
antirejection agent for reversing ongoing rejection, espe-
cially with acute rejection episodes, although it also ap-
pears effective in the treatment of chronic liver allograft 
rejection. The use of FK 506 appears to lower the steroid 
requirement, allowing monotherapy in approximately 30% 
to 50% of primary transplant recipients. FK 506-based 
immunosuppression is not associated with hirsuitism. or 
gingival hyperplasia, and appears to have a lower inci-
dence of hypertension. The adverse effects of FK 506 
include: nephrotoxicity, neurotoxicity (predominantly in 
liver transplant recipients), glucose intolerance, and hy-
perkalemia. 
Monoclonal antibodies with varying specificities have 
been developed to target specific interactions in the alloim-
mune response. Anti-CD4 monoclonal antibodies have 
been thought to target the helper T cell involved in the 
initial allorecognition and expansion phase of the immune 
response. Anti-IL-2 receptor monoclonal antibodies have 
been developed to the p55 component of IL-2 receptor of 
activated T cells, which will block the IL-2-driven T-cell 
proliferation. BMA 031 and TlOB9.1A-31 are monoclonal 
antibodies against a monomorphic determinant of the aJ (:f 
chain of the T-cell receptor. Like OKT3. they appear 
effective in the treatment of acute cellular rejection in 
kidney allograft recipients, except that they appear to be 
better tolerated. A number of monoclonal antibodies 
against cellular adhesion molecules have also been pre-
pared, such as ICAM-l (CD54) and LFA-l (CDll). Most 
of these monoclonal antibodies have shown promise in 
early clinical trials, although comparison to currently 
available antilymphocyte antibodies are underway. 
LIMITATIONS OF IMMUNOSUPPRESSION 
There are two limitations of the current and experimental 
immunosuppressive agents. The first is the potency of the 
agents, either alone or in combination with other agents, in 
preventing rejection. The other is the side effects associ-
ated with these agents. While each immunosuppressive 
agent is associated with specific side effects, a host of 
infectious and malignant complications arise from the use 
of nonspecific immunosuppressive agents. 
Certain types of noniymphoid. epithelial cancers have 
an increased incidence in patients on long-term immuno-
suppression. Azathioprine use is associated with a four-
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fold increase in the incidence of skin cancers. Kaposi 
sarcoma is associated with long-term Cy A immunosup-
pression. Reticulum cell sarcomas are increased approxi-
mately 350-fold, when compared to the general population. 
Posttransplant lymphoproliferative disease (PTLD) is an 
abnormality of lymphocyte proliferation in a setting of an 
immunosuppressed patient. The spectrum of PTLD can 
range from a benign lymphoid proliferation such as a 
mononucleosis syndrome to a frankly malignant lymphoid 
tumor. PTLD has been associated with all types of immu-
nosuppressive therapy, but the incidence is higher with the 
use of T -cell-specific immunosuppressive agents, such as 
Cy A and FK 506. The incidence of PTLD in the Cy A era 
is generally estimated between 2% and 4%. Most (90%) of 
PTLD are B cell in origin, and most are associated with 
integration of Epstein-Barr virus (EBV) DNA into the 
genome of the B cell. 
Cytomegalovirus is the most common opportunistic 
infection in the transplant patient, although the spectrum 
of opportunistic infections is quite large. Several factors 
determine the severity and development of CMV infec-
tions. The seronegativity and use of intensive immunosup-
pression are considered major contributing factors. The 
incidence of CMV infections in most series examining 
large numbers of transplant patients is between 20% and 
50%. This figure is dependent on the definition of CMV 
infections, since shedding of CMV virus can be asympto-
matic. Progression of disease to invasive CMV entails 
positive identification of the CMV virus or viral antigens in 
tissue. The sites of CMV infection. in decreasing order, 
include: GI tract (gastritis, enteritis, or colitis), liver, 
lungs, kidney, and eyes. The CNS can be affected by CMV 
invasion. The treatment of CMV is with the use of specific 
antiviral therapy and simultaneous reduction of immuno-
suppression. 
The other limitation of immunosuppression is the pa-
tency of the agents, either alone or in combination, in the 
prevention of rejection. Until the advent of Cy A, liver and 
heart allograft transplantation was only intermittently suc-
cessful. Even with CyA, -rejection rates are quite high (400/0 
to 70%), and the use of other agents have been proposed to 
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prevent or treat rejections seen with Cy A-based immuno-
suppression. Transplantation of "forbidden organs," eg, 
small bowel, lungs, and xenografts, have not proven 
successful with Cy A-based immunosuppression. FK S06 
has been utilized for clinical small bowel transplantation. 
with early success. to FK S06 appears more potent in the 
application of xenografting in animal models, II but in 
combination therapy with other agents, eg, RS61443, it 
appears to be even more efficacious. 
CONCLUSIONS 
Current day immunosuppression has led to success in a 
number of clinical transplant situations. Nevertheless. 
limitations of these agents exist, including inherent drug 
toxicity and the consequences of long-term immunosup-
pression. Newer agents may overcome some, but not all, 
of these limitations. The addition of the newer agents will 
allow transplant physicians to tailor immunosuppressive 
regimens with less toxicity and enhanced efficacy. 
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